CSPC Pharmaceutical Group Limited
CSPCY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,830 | $14,591 | $16,277 | $7,585 |
| % Growth | -87.5% | -10.4% | 114.6% | – |
| Cost of Goods Sold | $629 | $4,641 | $4,628 | $7,894 |
| Gross Profit | $1,201 | $9,950 | $11,649 | $18,678 |
| % Margin | 65.6% | 68.2% | 71.6% | 246.3% |
| R&D Expenses | $2,940 | $2,982 | $2,541 | $1,152 |
| G&A Expenses | $440 | $469 | $680 | $719 |
| SG&A Expenses | $3,781 | $4,553 | $5,813 | $5,382 |
| Sales & Mktg Exp. | $3,341 | $4,134 | $5,084 | $4,663 |
| Other Operating Expenses | $0 | -$11 | $11 | -$2,940 |
| Operating Expenses | $6,721 | $7,524 | $8,365 | $3,595 |
| Operating Income | $354 | $2,009 | $3,701 | $1,790 |
| % Margin | 19.4% | 13.8% | 22.7% | 23.6% |
| Other Income/Exp. Net | $76 | $127 | $99 | -$10 |
| Pre-Tax Income | $430 | $2,137 | $3,799 | $1,780 |
| Tax Expense | $596 | $570 | $749 | $1,005 |
| Net Income | $351 | $1,586 | $3,019 | $1,379 |
| % Margin | 19.2% | 10.9% | 18.5% | 18.2% |
| EPS | 0.12 | 0.48 | 1.08 | 1.44 |
| % Growth | -75% | -55.6% | -25% | – |
| EPS Diluted | 0.12 | 0.48 | 1.08 | 1.44 |
| Weighted Avg Shares Out | 2,858 | 2,935 | 2,960 | 2,963 |
| Weighted Avg Shares Out Dil | 2,858 | 2,935 | 2,960 | 2,963 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $117 | $0 | $0 |
| Interest Expense | $3 | $0 | $0 | $9 |
| Depreciation & Amortization | $657 | $766 | $550 | $0 |
| EBITDA | $3,481 | $2,498 | $4,525 | $1,789 |
| % Margin | 190.2% | 17.1% | 27.8% | 23.6% |